XML 41 R20.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segment Reporting and Foreign Operations | 12 Months Ended
--- | ---
Dec. 31, 2017
Segment Reporting [Abstract] |
Segment Reporting and Foreign Operations | SEGMENT REPORTING AND FOREIGN OPERATIONS We report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of cardiology and radiology medical device products which assist in diagnosing and treating coronary artery disease, peripheral vascular disease and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management ("CRM"), electrophysiology ("EP"), critical care and interventional oncology and spine devices. Our endoscopy segment consists of gastroenterology and pulmonology medical device products which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. We evaluate the performance of our operating segments based on operating income (loss). Listed below are the sales by business segment for the years ended December 31, 2017, 2016 and 2015 (in thousands):
| % Change |  | 2017 |  | % Change |  | 2016* |  | % Change |  | 2015
Cardiovascular |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stand-alone devices | 44% |  | $ | 275,431 |  |  | 23% |  | $ | 191,148 |  |  | 8% |  | $ | 155,414 |
Custom kits and procedure trays | 6% |  | 126,114 |  |  | 2% |  | 119,226 |  |  | 5% |  | 116,368 |
Inflation devices | 8% |  | 79,875 |  |  | 1% |  | 73,916 |  |  | 1% |  | 73,373 |
Catheters | 13% |  | 127,747 |  |  | 17% |  | 113,367 |  |  | 11% |  | 96,833 |
Embolization devices | 8% |  | 49,532 |  |  | 2% |  | 46,035 |  |  | 3% |  | 45,025 |
CRM/EP | 15% |  | 41,914 |  |  | 8% |  | 36,459 |  |  | 3% |  | 33,902 |
Total | 21% |  | 700,613 |  |  | 11% |  | 580,151 |  |  | 6% |  | 520,915 |
Endoscopy |  |  |  |  |  |  |  |  |  |  |  |  |  |
Endoscopy devices | 15% |  | 27,239 |  |  | 12% |  | 23,687 |  |  | 18% |  | 21,234 |
Total | 21% |  | $ | 727,852 |  |  | 11% |  | $ | 603,838 |  |  | 6% |  | $ | 542,149 |
* Certain product categories for 2016 have been adjusted from prior disclosure to reflect changes in product classifications to be consistent with updates in the management of our product portfolios in 2017. During the years ended December 31, 2017, 2016 and 2015, we had international sales of approximately $307.1 million, $233.5 million and $214.0 million, respectively, or approximately 42%, 39% and 39%, respectively, of net sales, primarily in China, Japan, Germany, France, the United Kingdom and Russia. China represents our most significant international sales market with sales of approximately $73.4 million, $59.9 million, and $50.7 million for the years ended December 31, 2017, 2016 and 2015, respectively. International sales are attributed based on location of the customer receiving the product. Our long-lived assets by geographic area at December 31, 2017, 2016 and 2015, consisted of the following (in thousands):
| 2017 |  | 2016 |  | 2015
United States | $ | 202,504 |  |  | $ | 194,715 |  |  | $ | 186,389 |
Ireland | 45,671 |  |  | 47,337 |  |  | 48,896 |
Other foreign countries | 44,645 |  |  | 34,521 |  |  | 32,493 |
Total | $ | 292,820 |  |  | $ | 276,573 |  |  | $ | 267,778 |
Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the years ended December 31, 2017, 2016 and 2015, are as follows (in thousands):
| 2017 |  | 2016 |  | 2015
Net Sales (1) |  |  |  |  |  |  |  |
Cardiovascular | $ | 700,613 |  |  | $ | 580,151 |  |  | $ | 520,915 |
Endoscopy | 27,239 |  |  | 23,687 |  |  | 21,234 |
Total net sales | 727,852 |  |  | 603,838 |  |  | 542,149 |
Operating expenses |  |  |  |  |  |  |  |
Cardiovascular | 281,095 |  |  | 218,659 |  |  | 187,492 |
Endoscopy | 12,089 |  |  | 11,490 |  |  | 10,746 |
Total operating expenses | 293,184 |  |  | 230,149 |  |  | 198,238 |
Operating income (loss) (1) |  |  |  |  |  |  |  |
Cardiovascular | 24,819 |  |  | 30,053 |  |  | 34,052 |
Endoscopy | 8,250 |  |  | 4,823 |  |  | 3,491 |
Total operating income | 33,069 |  |  | 34,876 |  |  | 37,543 |
Total other expense - net | 2,812 |  |  | (9,490 | ) |  | (6,343 | )
Income tax expense | 8,358 |  |  | 5,265 |  |  | 7,398 |
Net income | $ | 27,523 |  |  | $ | 20,121 |  |  | $ | 23,802 |
(1) Sales and operating income have been adjusted from prior disclosure to reflect changes in product classifications between our operating segments, which were made to be consistent with updates in the management of our product portfolios in 2017. Total assets by business segment at December 31, 2017, 2016 and 2015, consisted of the following (in thousands):
| 2017 |  | 2016 |  | 2015
Cardiovascular | $ | 1,103,806 |  |  | $ | 932,927 |  |  | $ | 767,952 |
Endoscopy | 8,005 |  |  | 9,876 |  |  | 10,776 |
Total | $ | 1,111,811 |  |  | $ | 942,803 |  |  | $ | 778,728 |
Total depreciation and amortization by business segment for the years ended December 31, 2017, 2016, and 2015 consisted of the following (in thousands):
| 2017 |  | 2016 |  | 2015
Cardiovascular | $ | 52,700 |  |  | $ | 42,806 |  |  | $ | 36,474 |
Endoscopy | 882 |  |  | 949 |  |  | 951 |
Total | $ | 53,582 |  |  | $ | 43,755 |  |  | $ | 37,425 |
Total capital expenditures for property and equipment by business segment for the years ended December 31, 2017, 2016 and 2015 consisted of the following (in thousands):
| 2017 |  | 2016 |  | 2015
Cardiovascular | $ | 38,437 |  |  | $ | 32,613 |  |  | $ | 50,927 |
Endoscopy | 186 |  |  | 224 |  |  | 32 |
Total | $ | 38,623 |  |  | $ | 32,837 |  |  | $ | 50,959 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration